Document Detail


Biphasic elimination of tenofovir diphosphate and nonlinear pharmacokinetics of zidovudine triphosphate in a microdosing study.
MedLine Citation:
PMID:  23187888     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: Phase 0 studies can provide initial pharmacokinetics (PKs) data in humans and help to facilitate early drug development, but their predictive value for standard dosing is controversial. To evaluate the prediction of microdosing for active intracellular drug metabolites, we compared the PK profile of 2 antiretroviral drugs, zidovudine (ZDV) and tenofovir (TFV), in microdose and standard dosing regimens.
STUDY DESIGN: We administered a microdose (100 μg) of C-labeled drug (ZDV or tenofovir disoproxil fumarate) with or without a standard unlabelled dose (300 mg) to healthy volunteers. Both the parent drug in plasma and the active metabolite, ZDV-triphosphate (ZDV-TP) or TFV-diphosphate (TFV-DP) in peripheral blood mononuclear cells (PBMCs) and CD4 cells were measured by accelerator mass spectrometry.
RESULTS: The intracellular ZDV-TP concentration increased less than proportionally over the dose range studied (100 μg-300 mg), whereas the intracellular TFV-DP PKs were linear over the same dose range. ZDV-TP concentrations were lower in CD4 cells versus total PBMCs, whereas TFV-DP concentrations were not different in CD4 cells and PBMCs.
CONCLUSIONS: Our data were consistent with a rate-limiting step in the intracellular phosphorylation of ZDV but not TFV. Accelerator mass spectrometry shows promise for predicting the PK of active intracellular metabolites of nucleosides, but nonlinearity of PK may be seen with some drugs.
Authors:
Jianmeng Chen; Charles Flexner; Rosa G Liberman; Paul L Skipper; Nicolette A Louissaint; Steven R Tannenbaum; Craig W Hendrix; Edward J Fuchs
Related Documents :
24094158 - Co-delivery of drug and dna from cationic dual-responsive micelles derived from poly(dm...
24858718 - Current advances on abc drug transporters in fish.
23289618 - Targeted drug delivery to macrophages.
18393808 - Use of microwave in processing of drug delivery systems.
24218778 - Opioid regulation: time to reconsider the nomenclature and approach.
19477668 - The psychology behind doping in sport.
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of acquired immune deficiency syndromes (1999)     Volume:  61     ISSN:  1944-7884     ISO Abbreviation:  J. Acquir. Immune Defic. Syndr.     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-11-28     Completed Date:  2013-02-04     Revised Date:  2014-03-19    
Medline Journal Info:
Nlm Unique ID:  100892005     Medline TA:  J Acquir Immune Defic Syndr     Country:  United States    
Other Details:
Languages:  eng     Pagination:  593-9     Citation Subset:  IM; X    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adenine / administration & dosage,  analogs & derivatives*,  blood,  pharmacokinetics
Adult
Anti-HIV Agents / administration & dosage*,  blood,  pharmacokinetics*
Biological Availability
CD4-Positive T-Lymphocytes / metabolism
Carbon Radioisotopes
Dideoxynucleotides / administration & dosage*,  blood,  pharmacokinetics*
Female
Humans
Male
Mass Spectrometry
Middle Aged
Organophosphonates / administration & dosage*,  blood,  pharmacokinetics*
Phosphorylation
Reverse Transcriptase Inhibitors / administration & dosage,  blood,  pharmacokinetics
Thymine Nucleotides / administration & dosage*,  blood,  pharmacokinetics*
Zidovudine / administration & dosage,  analogs & derivatives*,  blood,  pharmacokinetics
Grant Support
ID/Acronym/Agency:
UL1 RR025005/RR/NCRR NIH HHS; UL1-RR025005/RR/NCRR NIH HHS
Chemical
Reg. No./Substance:
0/Anti-HIV Agents; 0/Carbon Radioisotopes; 0/Dideoxynucleotides; 0/Organophosphonates; 0/Reverse Transcriptase Inhibitors; 0/Thymine Nucleotides; 0/tenofovir disoproxil; 4B9XT59T7S/Zidovudine; 92586-35-1/3'-azido-3'-deoxythymidine 5'-triphosphate; JAC85A2161/Adenine
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Reduced Levels of Serum FGF19 and Impaired Expression of Receptors for Endocrine FGFs in Adipose Tis...
Next Document:  Programmable complementary resistive switching behaviours of a plasma-oxidised titanium oxide nanola...